Improvement in childhood cancer survival in Lithuania over three decades

Fuente: Redalyc
Saved in:
Bibliographic Details
Main Author: Jelena Rascon
Format: Artículo científico
Language:en
Published: Vilniaus Universitetas 2020
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1876443075031597056
author Jelena Rascon
author_facet Jelena Rascon
contents Improvement in childhood cancer survival in Lithuania over three decades Jelena Rascon Giedrė Smailytė Medicina survival Lithuania Childhood cancer Population-based EUROCARE-5 studies demonstrated that childhood cancer survival rates in Lithuania were 10–20% lower than the European mean. We aimed to analyse the change in the outcome of treatment of paediatric malignancies in Lithuania over 30 years. Methods. A single-centre retrospective analysis of children below 18 years of age treated for cancer at Vilnius University Hospital Santa- ros Klinikos between 1982 and 2011 was carried out. The minimal re- quirement of 5-year follow-up after diagnosis was specified for survival estimation. The vital status was assessed using data from the popula- tion-based Lithuanian Cancer Registry. To evaluate changes over time, the entire cohort was split into three groups according to the time of diagnosis: 1982–1991, 1992–2001, and 2002–2011. Results. A total of 1268 children met the inclusion criteria. The shortest median follow-up was 8.9 (IQR 6.4–11.5) years for patients treated in the third decade. The 5-year overall survival of the entire co- hort increased from 37.3% (95% CI 30.2–44.3) in 1982–1991 to 70.7% (95% CI 66.4–74.1) in 2002–2011 (p < 0.0001). The same trend was ev- ident when calculated separately for leukaemia (p < 0.0001), lymphoma (p < 0.0005), and solid tumours (p < 0.004). The percentage of cure rose from zero in the early years of the period analysed to 80% in 2010 and 2011. The improvement in the treatment outcome was attributable to the reduction of treatment-related mortality from 45.8% in 1982–1991 to 12.4% in 2002–2011 and disease recurrence from 30.4% to 19.6% for the same periods, respectively. Conclusions. Significant progress in the cure rate of children treat- ed for cancer at our institution was observed over 30 years. Collabora- tive national and international clinical and research efforts are crucial to ensure further advances in care and cure. 2020 artículo científico 2029-4174 https://www.redalyc.org/articulo.oa?id=694073948006 https://www.redalyc.org/journal/6940/694073948006/ https://www.redalyc.org/journal/6940/694073948006/html/ https://www.redalyc.org/journal/6940/694073948006/694073948006.epub https://www.redalyc.org/journal/6940/694073948006/movil en http://www.redalyc.org/revista.oa?id=6940 Acta medica Lituanica application/pdf Vilniaus Universitetas Acta medica Lituanica (Lituania) Num.1 Vol.27
format Artículo científico
id redalyc_694073948006
institution Redalyc
language en
publishDate 2020
publisher Vilniaus Universitetas
spellingShingle Improvement in childhood cancer survival in Lithuania over three decades
Jelena Rascon
Medicina
survival
Lithuania
Childhood cancer
Improvement in childhood cancer survival in Lithuania over three decades Jelena Rascon Giedrė Smailytė Medicina survival Lithuania Childhood cancer Population-based EUROCARE-5 studies demonstrated that childhood cancer survival rates in Lithuania were 10–20% lower than the European mean. We aimed to analyse the change in the outcome of treatment of paediatric malignancies in Lithuania over 30 years. Methods. A single-centre retrospective analysis of children below 18 years of age treated for cancer at Vilnius University Hospital Santa- ros Klinikos between 1982 and 2011 was carried out. The minimal re- quirement of 5-year follow-up after diagnosis was specified for survival estimation. The vital status was assessed using data from the popula- tion-based Lithuanian Cancer Registry. To evaluate changes over time, the entire cohort was split into three groups according to the time of diagnosis: 1982–1991, 1992–2001, and 2002–2011. Results. A total of 1268 children met the inclusion criteria. The shortest median follow-up was 8.9 (IQR 6.4–11.5) years for patients treated in the third decade. The 5-year overall survival of the entire co- hort increased from 37.3% (95% CI 30.2–44.3) in 1982–1991 to 70.7% (95% CI 66.4–74.1) in 2002–2011 (p < 0.0001). The same trend was ev- ident when calculated separately for leukaemia (p < 0.0001), lymphoma (p < 0.0005), and solid tumours (p < 0.004). The percentage of cure rose from zero in the early years of the period analysed to 80% in 2010 and 2011. The improvement in the treatment outcome was attributable to the reduction of treatment-related mortality from 45.8% in 1982–1991 to 12.4% in 2002–2011 and disease recurrence from 30.4% to 19.6% for the same periods, respectively. Conclusions. Significant progress in the cure rate of children treat- ed for cancer at our institution was observed over 30 years. Collabora- tive national and international clinical and research efforts are crucial to ensure further advances in care and cure. 2020 artículo científico 2029-4174 https://www.redalyc.org/articulo.oa?id=694073948006 https://www.redalyc.org/journal/6940/694073948006/ https://www.redalyc.org/journal/6940/694073948006/html/ https://www.redalyc.org/journal/6940/694073948006/694073948006.epub https://www.redalyc.org/journal/6940/694073948006/movil en http://www.redalyc.org/revista.oa?id=6940 Acta medica Lituanica application/pdf Vilniaus Universitetas Acta medica Lituanica (Lituania) Num.1 Vol.27
title Improvement in childhood cancer survival in Lithuania over three decades
topic Medicina
survival
Lithuania
Childhood cancer
url https://www.redalyc.org/articulo.oa?id=694073948006
https://www.redalyc.org/journal/6940/694073948006/
https://www.redalyc.org/journal/6940/694073948006/html/
https://www.redalyc.org/journal/6940/694073948006/694073948006.epub
https://www.redalyc.org/journal/6940/694073948006/movil